Thông tin thuốc gốc
Chỉ định và Liều dùng
Abdominal infections, Respiratory tract infections, Skin and skin structure infections, Urinary tract infections
Adult: Mild to moderate infections: 1-2 g daily in 2 divided doses. Severe infections: Up to 4 g daily in 2 divided doses. Doses are given by deep IM inj or IV infusion over at least 30 min.
Child: Neonates: 30 mg/kg 12 hrly, may increase to 50 mg/kg for Pseudomonas infections; >30 days Mild to moderate infections: 100 mg/kg daily in 2 divided doses. Severe infections: Up to 150 mg/kg daily in 2 or 3 divided doses. Total dose should not exceed the recommended adult dosage.

Empiric therapy for febrile neutropenic patients
Adult: Up to 6 g daily in 3 divided doses. Doses are given by deep IM inj or IV infusion over at least 30 min.
Special Patient Group
Critically ill patients undergoing continuous renal replacement therapy: Loading dose: 2 g. Maintenance dose: Continuous venovenous haemofiltration (CVVH): 1-2 g 12 hrly. Continuous venovenous haemodialysis (CVVHD) and haemodiafiltration (CVVHDF): 1 g 8 hrly or 2 g 12 hrly.
Renal Impairment
Abdominal infections, Urinary tract infections, Respiratory tract infection, Skin and skin structure infections: Haemodialysis: 1 g on the 1st day of treatment, followed by 0.5 g daily; dose given after haemodialysis. CAPD: Adult dose given 48 hrly.
CrCl Dosage
≤10 0.25-0.5 g 24 hrly.
11-29 0.5-1 g 24 hrly.
30-60 0.5-2 g 24 hrly.
Empiric therapy for febrile neutropenic patients: Haemodialysis patients: 1 g daily. CAPD: 2 g 48 hrly.
CrCl Dosage
≤10 1 g 24 hrly.
11-29 2 g 24 hrly.
30-60 2 g 12 hrly.
Hướng dẫn pha thuốc
IV infusion: Add 5 mL, 10 mL, or 10 mL of a compatible IV soln to a vial labeled as containing 500 mg, 1 g, or 2 g, respectively, to provide soln containing approx 100 mg/mL, 100 mg/mL, or 160 mg/mL of the drug, respectively. The appropriate dose of the drug should then be added to a compatible IV soln. IM inj: Add 1.3 mL or 2.4 mL of an appropriate diluent (e.g. sterile water for inj, NaCl 0.9%) to a vial labeled as containing 500 mg or 1 g respectively, to provide a soln containing approx 280 mg/mL.
Tương kỵ
Y-site: Acetylcysteine, aciclovir, amphotericin B, amphotericin B cholesteryl sulfate complex, caspofungin, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, dacarbazine, daunorubicin, diazepam, diphenhydramine, doxorubicin, droperidol, enalaprilat, erythromycin lactobionate, etoposide, etoposide phosphate, famotidine, filgrastim, floxuridine, gallium nitrate, ganciclovir, haloperidol, hydroxyzine, idarubicin, ifosfamide, Mg sulfate, mannitol, mechlorethamine, meperidine, metoclopramide, midazolam, mitomycin, mitoxantrone, morphine, nalbuphine, nicardipine, ondansetron, phenytoin, prochlorperazine edisylate, promethazine, streptozocin, theophylline, vinblastine, vincristine.
Chống chỉ định
Hypersensitivity to cefepime or other cephalosporins.
Thận trọng
Hypersensitivity to penicillins or other β-lactam antibiotics. Patient w/ history of seizure disorder, history of GI disease, particularly colitis. Renal impairment. Pregnancy and lactation. Prolonged use may result in overgrowth of non-susceptible organisms.
Phản ứng phụ
Headache, rash, diarrhoea, nausea, vomiting, local reactions (e.g. phlebitis, pain and/or inflammation), neutropenia, positive direct Coombs' test.
Potentially Fatal: Neurotoxicity (e.g. encephalopathy, myoclonus, seizures, non-convulsive status epilepticus); Clostridium difficile-associated diarrhoea; anaphylaxis.
IM/IV/Parenteral: B
Monitor renal function; signs and symptoms of anaphylaxis during 1st dose.
Quá liều
Symptoms: Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, neuromuscular excitability and non-convulsive status epilepticus. Management: Supportive treatment. Haemodialysis is recommended in case of renal insufficiency.
Tương tác
Increased potential for nephrotoxicity and ototoxicity of aminoglycosides. Increased risk of nephrotoxicity w/ potent diuretics (e.g. furosemide).
Lab Interference
False positive reaction for urine glucose test using Clinitest tablets.
Tác dụng
Description: Cefepime inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested.
Absorption: Rapidly and almost completely absorbed on IM inj. Time to peak plasma concentration: Approx 1.5 hr (IM); w/in 30 min (IV).
Distribution: Widely distributed in body tissues and fluids; high concentrations in bile. Crosses the blood-brain barrier and enters breast milk (low concentrations). Volume of distribution: 16-20 L. Plasma protein binding: Approx 20%.
Metabolism: Minimally hepatic.
Excretion: Via urine (approx 85% as unchanged drug). Plasma half-life: Approx 2 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Cefepime, CID=5479537, https://pubchem.ncbi.nlm.nih.gov/compound/Cefepime (accessed on Jan. 21, 2020)

Bảo quản
Store between 20-25°C. Protect from light.
Phân loại MIMS
Anon. Cefepime. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/11/2014.

Buckingham R (ed). Cefepime Hydrochloride . Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2014.

Cefepime Hydrochloride Injection, Powder, for Solution (Fresenius Kabi USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 11/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Cefepime Hydrochloride . AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 11/11/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Cefepime từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Amfapime
  • Capime
  • Cefepim Euvipharm
  • Cefepim Stada Pymepharco
  • Cefepima Libra
  • Cefepimark
  • Cefepime Samrudh
  • Ceficad
  • Cefpin
  • Cepimstad
  • Dalipim
  • Donzime
  • Epepim
  • Flamipime
  • Forpar
  • Maxapin
  • Maxipime
  • Micropime
  • Monalis
  • Muscef
  • Osiafra
  • Penfepim
  • Pozineg
  • Ropiro
  • Safepim
  • Shinfepim
  • Spectrax
  • Suprapime
  • Tocetix
  • Ulticef
  • Uniceme
  • Vifepime
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in